These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25781535)
1. Monitoring gonadotropin-releasing hormone analogue (GnRHa) treatment in girls with central precocious puberty: a comparison of four methods. Zung A; Burundukov E; Ulman M; Glaser T; Zadik Z J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):885-93. PubMed ID: 25781535 [TBL] [Abstract][Full Text] [Related]
2. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. Garibaldi LR; Aceto T; Weber C; Pang S J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395 [TBL] [Abstract][Full Text] [Related]
3. The Use of Morning Urinary Gonadotropins and Sex Hormones in the Management of Early Puberty in Chinese Girls. Zhan S; Huang K; Wu W; Zhang D; Liu A; Dorazio RM; Shi J; Ullah R; Zhang L; Wang J; Dong G; Ni Y; Fu J J Clin Endocrinol Metab; 2021 Oct; 106(11):e4520-e4530. PubMed ID: 34160619 [TBL] [Abstract][Full Text] [Related]
4. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty. Tao Y; Si C; Li H; Han J; Hou H; Yang M Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of basal LH in monitoring central precocious puberty treatment in girls. Calcaterra V; De Filippo G; Albertini R; Rendina D; Messini B; Monti CM; Bozzola E; Villani A; Bozzola M J Pediatr Endocrinol Metab; 2021 Jan; 34(1):45-50. PubMed ID: 33189082 [TBL] [Abstract][Full Text] [Related]
6. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment. Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment. Yüce Ö; Bideci A; Çelik N; Çamurdan O; Cinaz P Arch Endocrinol Metab; 2020 Apr; 64(2):121-127. PubMed ID: 32236310 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study. Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center. Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062 [TBL] [Abstract][Full Text] [Related]
11. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. Lee PA; Luce M; Bacher P J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929 [TBL] [Abstract][Full Text] [Related]
12. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399 [TBL] [Abstract][Full Text] [Related]
13. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty. Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097 [TBL] [Abstract][Full Text] [Related]
14. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. Tung YC; Lee JS; Tsai WY; Hsiao PH J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961 [TBL] [Abstract][Full Text] [Related]
15. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty. Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449 [TBL] [Abstract][Full Text] [Related]
16. The histrelin implant: a novel treatment for central precocious puberty. Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137 [TBL] [Abstract][Full Text] [Related]
17. [The significance and characteristics of the LHRH test in diagnosing precocious puberty development in girls: the stimulated LH/FSH quotient differentiates between central precocious puberty and premature thelarche]. Partsch CJ; Hümmelink R; Lorenzen F; Sippell WG Monatsschr Kinderheilkd; 1989 May; 137(5):284-8. PubMed ID: 2525665 [TBL] [Abstract][Full Text] [Related]
18. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. Liang Y; Wei H; Li J; Hou L; Zhang J; Wu W; Ying Y; Luo X J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):839-46. PubMed ID: 25719299 [TBL] [Abstract][Full Text] [Related]
19. Peak serum luteinising hormone cut-off during gonadotropin-releasing hormone analogue test for diagnosing central precocious puberty was lower in girls with obesity as compared with girls with normal weight. Sakornyutthadej N; Mahachoklertwattana P; Wankanit S; Poomthavorn P Clin Endocrinol (Oxf); 2024 Apr; 100(4):368-378. PubMed ID: 38300440 [TBL] [Abstract][Full Text] [Related]
20. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty]. Liang Y; Wei H; Zhang JL; Hou L; Luo XP Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]